Symbols / TWST $59.81 +6.37% Twist Bioscience Corporation

Healthcare • Diagnostics & Research • United States • NMS
TWST Chart
About

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Diagnostics & Research Market Cap 3.67B
Enterprise Value 3.58B Income -76.58M Sales 391.56M
Book/sh 7.44 Cash/sh 3.23 Dividend Yield —
Payout 0.00% Employees 979 IPO —
P/E — Forward P/E -31.73 PEG —
P/S 9.37 P/B 8.03 P/C —
EV/EBITDA -31.77 EV/Sales 9.15 Quick Ratio 3.08
Current Ratio 3.78 Debt/Eq 24.79 LT Debt/Eq —
EPS (ttm) -1.27 EPS next Y -1.89 EPS Growth —
Revenue Growth 16.90% Earnings 2026-05-04 ROA -13.49%
ROE -16.79% ROIC — Gross Margin 51.62%
Oper. Margin -31.73% Profit Margin -19.56% Shs Outstand 61.31M
Shs Float 54.55M Short Float 29.74% Short Ratio 13.07
Short Interest — 52W High 61.61 52W Low 23.30
Beta 2.21 Avg Volume 1.29M Volume 1.52M
Target Price $52.56 Recom Strong_buy Prev Close $56.23
Price $59.81 Change 6.37%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$52.56
Mean price target
2. Current target
$59.81
Latest analyst target
3. DCF / Fair value
$-13.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$59.81
Low
$36.00
High
$58.00
Mean
$52.56

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 main Barclays Overweight → Overweight $55
2026-04-06 main Evercore ISI Group Outperform → Outperform $56
2026-03-30 main Guggenheim Buy → Buy $55
2026-02-03 main Evercore ISI Group Outperform → Outperform $52
2026-02-03 main Barclays Overweight → Overweight $50
2026-01-26 main Guggenheim Buy → Buy $50
2026-01-08 main TD Cowen Buy → Buy $43
2025-12-15 main Barclays Overweight → Overweight $39
2025-11-17 main Barclays Overweight → Overweight $37
2025-11-04 init Stephens & Co. — → Overweight $41
2025-10-07 main Evercore ISI Group Outperform → Outperform $42
2025-10-02 main Barclays Overweight → Overweight $40
2025-05-06 main Goldman Sachs Buy → Buy $48
2025-05-06 reit Guggenheim Buy → Buy $50
2025-05-06 main Baird Outperform → Outperform $44
2025-05-06 main JP Morgan Underweight → Underweight $33
2025-04-10 main Barclays Overweight → Overweight $45
2025-02-04 main Scotiabank Sector Outperform → Sector Outperform $62
2025-02-04 main JP Morgan Underweight → Underweight $40
2025-02-04 main Baird Outperform → Outperform $54
News
RSS: Latest TWST news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 LAPONIS ADAM Chief Financial Officer — 3,000 $55.00 $165,000
2026-04-09 LAPONIS ADAM Chief Financial Officer — 2,597 $49.89 $129,562
2026-04-01 STAROVASNIK MELISSA A Director — 1,000 $51.00 $51,000
2026-03-20 GREEN PAULA Officer — 297 $43.79 $13,005
2026-03-20 CHO DENNIS Officer — 354 $43.79 $15,500
2026-03-20 LEPROUST EMILY M Chief Executive Officer — 1,742 $43.79 $76,276
2026-03-17 CHESS ROBERT BRUCE Director — 10,000 $47.00 $470,000
2026-03-17 CHESS ROBERT BRUCE Director — 10,000 $11.89 $118,900
2026-03-06 GREEN PAULA Officer — 935 $46.43 $43,408
2026-03-06 WERNER ROBERT F. Officer — 246 $46.43 $11,421
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
376.57
+20.32%
312.97
+27.69%
245.11
+20.41%
203.56
Operating Revenue
376.57
+20.32%
312.97
+27.69%
245.11
+20.41%
203.56
Cost Of Revenue
185.57
+3.31%
179.62
+15.60%
155.38
+30.21%
119.33
Reconciled Cost Of Revenue
185.57
+3.31%
179.62
+15.60%
155.38
+30.21%
119.33
Gross Profit
191.00
+43.23%
133.35
+48.61%
89.73
+6.52%
84.23
Operating Expense
327.26
+5.82%
309.25
+4.25%
296.63
-10.99%
333.26
Research And Development
80.28
-11.63%
90.85
-15.01%
106.89
-11.15%
120.31
Selling General And Administration
246.98
+13.09%
218.40
+15.11%
189.74
-10.90%
212.95
Total Expenses
512.83
+4.90%
488.88
+8.16%
452.01
-0.13%
452.59
Operating Income
-136.26
+22.54%
-175.90
+14.98%
-206.90
+16.91%
-249.02
Total Operating Income As Reported
-136.26
+38.30%
-220.83
-1.69%
-217.16
+7.50%
-234.78
EBITDA
-111.41
+22.89%
-144.47
+18.65%
-177.59
+16.10%
-211.68
Normalized EBITDA
-160.25
-61.00%
-99.54
+40.52%
-167.34
+27.41%
-230.53
Reconciled Depreciation
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
EBIT
-136.26
+22.54%
-175.90
+14.98%
-206.90
+9.33%
-228.19
Total Unusual Items
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Total Unusual Items Excluding Goodwill
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Special Income Charges
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Impairment Of Capital Assets
0.00
-100.00%
44.93
+562.20%
6.79
0.00
Restructuring And Mergern Acquisition
0.00
0.00
-100.00%
3.47
+124.37%
-14.24
Net Income
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Pretax Income
-76.95
+63.03%
-208.17
-2.31%
-203.47
+10.87%
-228.27
Net Non Operating Interest Income Expense
11.36
-25.94%
15.34
+6.82%
14.37
+381.72%
2.98
Interest Expense Non Operating
—
0.03
+480.00%
0.01
-93.75%
0.08
Net Interest Income
11.36
-25.94%
15.34
+6.82%
14.37
+381.72%
2.98
Interest Expense
—
0.03
+480.00%
0.01
-93.75%
0.08
Interest Income Non Operating
11.36
-25.94%
15.34
+6.82%
14.37
+369.14%
3.06
Interest Income
11.36
-25.94%
15.34
+6.82%
14.37
+369.14%
3.06
Other Income Expense
47.94
+200.70%
-47.61
-335.66%
-10.93
-161.51%
17.77
Other Non Operating Income Expenses
-0.90
+66.29%
-2.68
-298.66%
-0.67
+38.18%
-1.09
Gain On Sale Of Business
48.85
0.00
0.00
-100.00%
4.61
Tax Provision
0.72
+28.39%
0.56
-51.39%
1.15
+111.07%
-10.41
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+320.00%
0.00
Tax Effect Of Unusual Items
10.26
0.00
+100.00%
-2.15
-328.49%
0.94
Net Income Including Noncontrolling Interests
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income From Continuing Operation Net Minority Interest
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income From Continuing And Discontinued Operation
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income Continuous Operations
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Normalized Income
-116.26
+29.02%
-163.80
+16.65%
-196.52
+16.65%
-235.77
Net Income Common Stockholders
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Diluted EPS
-1.30
+63.89%
-3.60
+0.00%
-3.60
+10.89%
-4.04
Basic EPS
-1.30
+63.89%
-3.60
+0.00%
-3.60
+10.89%
-4.04
Basic Average Shares
59.81
+3.09%
58.02
+1.99%
56.88
+5.57%
53.88
Diluted Average Shares
59.81
+3.09%
58.02
+1.99%
56.88
+5.57%
53.88
Diluted NI Availto Com Stockholders
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
641.86
+4.48%
614.32
-20.88%
776.40
-19.24%
961.38
Current Assets
332.97
-3.98%
346.78
-18.26%
424.26
-28.87%
596.48
Cash Cash Equivalents And Short Term Investments
232.43
-15.91%
276.40
-17.84%
336.41
-33.38%
504.97
Cash And Cash Equivalents
183.05
-19.12%
226.32
-21.00%
286.47
-24.35%
378.69
Cash Equivalents
150.37
-24.76%
199.86
-18.64%
245.65
—
Cash Financial
32.68
+23.51%
26.46
-35.18%
40.82
—
Other Short Term Investments
49.38
-1.39%
50.08
+0.28%
49.94
-60.45%
126.28
Receivables
57.02
+63.36%
34.90
-20.79%
44.06
+9.36%
40.29
Accounts Receivable
57.02
+63.36%
34.90
-20.79%
44.06
+9.36%
40.29
Gross Accounts Receivable
57.62
+61.84%
35.60
-19.57%
44.26
+9.31%
40.49
Allowance For Doubtful Accounts Receivable
-0.60
+14.29%
-0.70
-250.00%
-0.20
+0.00%
-0.20
Receivables Adjustments Allowances
—
—
—
-0.23
Other Receivables
—
—
—
4.82
Inventory
28.31
+17.57%
24.08
-24.90%
32.06
-18.43%
39.31
Raw Materials
20.19
+16.60%
17.32
-35.92%
27.02
-6.12%
28.79
Work In Process
2.27
+5.55%
2.15
+92.81%
1.11
-61.17%
2.87
Finished Goods
5.85
+26.80%
4.62
+17.58%
3.93
-48.71%
7.65
Prepaid Assets
—
—
—
11.91
Other Current Assets
15.20
+33.42%
11.40
-2.73%
11.72
-1.66%
11.91
Total Non Current Assets
308.89
+15.45%
267.55
-24.02%
352.15
-3.49%
364.90
Net PPE
151.66
-6.00%
161.35
-20.66%
203.36
-5.14%
214.39
Gross PPE
246.65
+4.08%
236.99
-6.70%
254.02
+3.19%
246.17
Accumulated Depreciation
-94.99
-25.58%
-75.64
-49.33%
-50.66
-59.41%
-31.78
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
17.30
+4.86%
16.50
+35.47%
12.18
+78.06%
6.84
Construction In Progress
20.12
+329.10%
4.69
-45.03%
8.53
-90.28%
87.72
Other Properties
150.96
-4.67%
158.36
-10.04%
176.04
+28.28%
137.23
Leases
58.28
+1.44%
57.45
+0.31%
57.27
+298.52%
14.37
Goodwill And Other Intangible Assets
95.62
-4.66%
100.29
-28.52%
140.29
-3.61%
145.55
Goodwill
82.19
-4.21%
85.81
+0.00%
85.81
+0.00%
85.81
Other Intangible Assets
13.43
-7.27%
14.48
-73.43%
54.48
-8.80%
59.74
Investments And Advances
54.34
+3463.08%
1.52
—
—
Other Non Current Assets
7.28
+66.01%
4.38
-48.37%
8.49
+71.31%
4.96
Total Liabilities Net Minority Interest
168.90
+19.25%
141.63
-7.41%
152.97
-11.06%
171.99
Current Liabilities
91.41
+28.73%
71.01
-3.16%
73.32
-19.13%
90.66
Payables And Accrued Expenses
38.69
+98.83%
19.46
-33.31%
29.18
-13.98%
33.92
Payables
15.64
+259.06%
4.36
-76.36%
18.43
-22.43%
23.75
Accounts Payable
11.09
+580.61%
1.63
-88.40%
14.05
-30.06%
20.09
Other Payable
—
—
—
—
Current Accrued Expenses
23.05
+52.63%
15.10
+40.45%
10.75
+5.75%
10.17
Pensionand Other Post Retirement Benefit Plans Current
31.29
-7.02%
33.65
+30.34%
25.82
-4.46%
27.02
Total Tax Payable
4.54
+66.72%
2.73
-37.70%
4.37
+19.48%
3.66
Current Debt And Capital Lease Obligation
13.82
-6.64%
14.80
-0.61%
14.90
+9.19%
13.64
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
13.82
-6.64%
14.80
-0.61%
14.90
+9.19%
13.64
Current Deferred Liabilities
6.88
+223.04%
2.13
-28.94%
3.00
-13.72%
3.48
Current Deferred Revenue
6.88
+223.04%
2.13
-28.94%
3.00
-13.72%
3.48
Other Current Liabilities
0.72
-24.87%
0.96
+123.49%
0.43
-96.59%
12.60
Total Non Current Liabilities Net Minority Interest
77.50
+9.73%
70.63
-11.32%
79.65
-2.07%
81.33
Long Term Debt And Capital Lease Obligation
61.75
-12.06%
70.22
-11.31%
79.17
-2.58%
81.27
Long Term Capital Lease Obligation
61.75
-12.06%
70.22
-11.31%
79.17
-2.58%
81.27
Non Current Deferred Liabilities
15.00
0.00
—
—
Non Current Deferred Revenue
15.00
0.00
—
—
Other Non Current Liabilities
0.75
+83.54%
0.41
-14.32%
0.47
+691.67%
0.06
Stockholders Equity
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Common Stock Equity
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
60.63
+2.98%
58.88
+2.29%
57.56
+1.83%
56.52
Ordinary Shares Number
60.63
+2.98%
58.88
+2.29%
57.56
+1.83%
56.52
Additional Paid In Capital
1,793.16
+4.55%
1,715.12
+3.49%
1,657.22
+2.32%
1,619.64
Retained Earnings
-1,319.58
-6.25%
-1,241.91
-20.22%
-1,033.03
-24.70%
-828.42
Gains Losses Not Affecting Retained Earnings
-0.63
-20.11%
-0.52
+30.95%
-0.76
+58.98%
-1.84
Other Equity Adjustments
-0.63
-20.11%
-0.52
+30.95%
-0.76
+58.98%
-1.84
Total Equity Gross Minority Interest
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Total Capitalization
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Working Capital
241.56
-12.41%
275.77
-21.42%
350.93
-30.62%
505.82
Invested Capital
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Total Debt
75.57
-11.12%
85.03
-9.61%
94.07
-0.89%
94.91
Capital Lease Obligations
75.57
-11.12%
85.03
-9.61%
94.07
-0.89%
94.91
Net Tangible Assets
377.34
+1.33%
372.40
-22.92%
483.14
-24.96%
643.84
Tangible Book Value
377.34
+1.33%
372.40
-22.92%
483.14
-24.96%
643.84
Available For Sale Securities
54.34
+3463.08%
1.52
—
—
Investmentin Financial Assets
54.34
+3463.08%
1.52
—
—
Non Current Note Receivables
—
—
—
0.00
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-47.63
+25.69%
-64.09
+55.01%
-142.47
-14.54%
-124.39
Cash Flow From Continuing Operating Activities
-47.63
+25.69%
-64.09
+55.01%
-142.47
-14.54%
-124.39
Net Income From Continuing Operations
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Depreciation Amortization Depletion
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
Depreciation And Amortization
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
Other Non Cash Items
2.18
+12.87%
1.93
+160.06%
-3.22
-144.33%
7.26
Stock Based Compensation
64.46
+26.58%
50.92
+68.19%
30.28
-61.99%
79.66
Provisionand Write Offof Assets
—
—
—
-0.01
Asset Impairment Charge
0.00
-100.00%
44.93
+562.20%
6.79
0.00
Operating Gains Losses
-48.85
—
—
-4.61
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-12.61
-181.80%
15.41
+1627.35%
-1.01
+81.16%
-5.36
Change In Receivables
-22.38
-365.06%
8.44
+295.46%
-4.32
+55.10%
-9.62
Changes In Account Receivables
-22.38
-365.06%
8.44
+295.46%
-4.32
+55.10%
-9.62
Change In Inventory
-4.23
-152.96%
7.99
+10.33%
7.24
+196.05%
-7.54
Change In Prepaid Assets
-3.72
-1073.04%
0.38
+109.17%
-4.17
-63.31%
-2.55
Change In Payables And Accrued Expense
12.68
+2514.02%
0.48
+147.13%
-1.03
-107.09%
14.50
Change In Accrued Expense
3.35
-72.77%
12.29
+730.97%
1.48
-79.23%
7.12
Change In Payable
9.33
+179.05%
-11.80
-370.69%
-2.51
-133.97%
7.38
Change In Account Payable
9.33
+179.05%
-11.80
-370.69%
-2.51
-133.97%
7.38
Change In Other Working Capital
—
—
—
4.85
Change In Other Current Assets
-1.57
-463.81%
0.43
-68.68%
1.38
-81.08%
7.27
Change In Other Current Liabilities
6.61
+385.37%
-2.32
-2045.37%
-0.11
+98.55%
-7.42
Investing Cash Flow
-24.76
-706.32%
-3.07
-106.07%
50.61
+121.73%
-232.93
Cash Flow From Continuing Investing Activities
-24.76
-706.32%
-3.07
-106.07%
50.61
+121.73%
-232.93
Net PPE Purchase And Sale
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Purchase Of PPE
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Capital Expenditure
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Net Investment Purchase And Sale
0.74
-62.99%
2.00
-97.44%
78.39
+166.91%
-117.16
Purchase Of Investment
-49.39
+4.84%
-51.91
+32.01%
-76.34
+64.92%
-217.64
Sale Of Investment
50.13
-7.00%
53.91
-65.16%
154.74
+54.00%
100.48
Net Business Purchase And Sale
2.50
0.00
0.00
+100.00%
-13.91
Purchase Of Business
—
0.00
0.00
+100.00%
-13.91
Gain Loss On Sale Of Business
-48.85
0.00
0.00
+100.00%
-4.61
Net Other Investing Changes
—
—
—
-5.75
Financing Cash Flow
28.54
+314.22%
6.89
+656.31%
0.91
-99.66%
270.53
Cash Flow From Continuing Financing Activities
28.54
+314.22%
6.89
+656.31%
0.91
-99.66%
270.53
Net Issuance Payments Of Debt
—
0.00
0.00
+100.00%
-1.56
Repayment Of Debt
—
0.00
0.00
+100.00%
-1.56
Long Term Debt Payments
—
0.00
0.00
+100.00%
-1.56
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-1.56
Net Common Stock Issuance
-0.02
+99.60%
-3.98
+9.76%
-4.41
-101.68%
262.07
Common Stock Payments
-0.02
+99.60%
-3.98
+9.76%
-4.41
+43.19%
-7.75
Repurchase Of Capital Stock
-0.02
+99.60%
-3.98
+9.76%
-4.41
+43.19%
-7.75
Proceeds From Stock Option Exercised
13.56
+24.77%
10.87
+104.38%
5.32
-46.97%
10.02
Net Other Financing Charges
15.00
—
—
—
Changes In Cash
-43.85
+27.25%
-60.27
+33.73%
-90.95
-4.81%
-86.78
Effect Of Exchange Rate Changes
0.14
+13.49%
0.13
+566.67%
-0.03
+91.54%
-0.32
Beginning Cash Position
229.13
-20.79%
289.28
-23.93%
380.26
-18.64%
467.36
End Cash Position
185.43
-19.08%
229.13
-20.79%
289.28
-23.93%
380.26
Free Cash Flow
-75.63
-9.34%
-69.17
+59.37%
-170.25
+24.75%
-226.24
Interest Paid Supplemental Data
—
0.00
0.00
-100.00%
0.01
Income Tax Paid Supplemental Data
0.68
+98.55%
0.34
-18.10%
0.42
+70.73%
0.25
Amortization Of Securities
—
—
—
1.31
Common Stock Issuance
—
0.00
0.00
-100.00%
269.82
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
269.82
Sale Of Business
2.50
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category